Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Eseroline is a small molecule alkaloid and the phenolic metabolite of physostigmine (eserine), produced by the hydrolysis of the carbamate group. Unlike its parent compound, which is a potent acetylcholinesterase inhibitor used in the treatment of glaucoma and anticholinergic toxicity, eseroline is primarily recognized for its potent analgesic activity. This effect is largely mediated through its role as an agonist at mu and delta opioid receptors, although it also retains some inhibitory activity against acetylcholinesterase. Eseroline has been extensively used in pharmacological research to investigate the structure-activity relationships of Calabar bean alkaloids and to study the dual opioid and cholinergic properties of related compounds. It is not currently used in clinical practice but remains a significant compound in neuropharmacological studies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on eseroline.